Synthesis and evaluation of a novel TcN(PNP)-complex with metronidazole isocyanide ligand as a marker for tumor hypoxia.

The [TcN(PNP)] core offers a unique route for the preparation of asymmetric Tc-complexes. Though bidentate chelators such as dithiocarbamates are most commonly used ligands in this approach, present study explores the possibility of using a monodentate ligand, a isocyanide derivative of metronidazole (MetroNC), for preparing a TcN(PNP) complex for detecting tumor hypoxia. MetroNC could be prepared in good yield and subsequently radiolabeled with [TcN(PNP)] precursor complex prepared from [TcN] core and N-(2-methoxyethyl)-2-(diphenylphosphino)- N-(2-(diphenylphosphino)ethyl)ethanamine (PNP2) ligand. Preliminary biodistribution studies showed tumor uptake pattern similar to previous studies wherein, about 75 % of the tumor activity observed at 60 min post injection (p.i.) was still found to remain in tumor at 180 min p.i. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Radioanalytical & Nuclear Chemistry is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)